Incidence of Neoplasms in Patients Who Develop Sustained Leukopenia During or After Treatment With 6-Mercaptopurine for Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 8, 2006, Pages 1025-1029

  Disanti, William ^a   Rajapakse, Ramona O ^a   Korelitz, Burton I ^a   Panagopoulos, Georgia ^a   Bratcher, Jason ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG INDUCED CANCER; ENTERITIS; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MEDICAL RECORD; NONHODGKIN LYMPHOMA; POST HOC ANALYSIS; STATISTICAL SIGNIFICANCE;

6-MERCAPTOPURINE; ADULT; AGED; CASE-CONTROL STUDIES; DATABASES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 33746370700     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.03.018     Document Type: Article

References (25)

1. Korelitz B.I., and Wisch N. Long term therapy of ulcerative colitis with 6-mercaptopurine. a personal series. Am J Dig Dis 17 (1972) 111-118
2. Adler D.J., and Korelitz B.I. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 85 (1990) 717-722
3. Su C.G., Stein R.B., Lewis J.D., et al. Azathioprine or 6-mercaptopurine for inflammatory bowel disease. do risks outweigh benefits?. Dig Liver Dis 32 (2000) 518-531
4. Present D.H., Korelitz B.I., Wisch N., et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302 (1980) 981-987
5. Korelitz B.I., Adler D.J., Mendelsohn R.A., et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 88 (1993) 1198-1205
6. Hanauer S.B., Korelitz B.I., Rutgeerts P., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo. a 2- year trial. Gastroenterology 127 (2004) 723-729
7. Korelitz B.I., Mirsky F.J., Fleisher M.R., et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 94 (1999) 3248-3253
8. Warman J.I., Korelitz B.I., Fleisher M.R., et al. Cumulative experience with short and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 37 (2003) 220-225
9. Connell W.R., Kamm M.A., Dickson M., et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343 (1994) 1249-1252
10. Fraser A.G., Orchard T.R., Robinson E.M., et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 16 (2002) 1225-1232
11. Farrell R.J., Ang Y., Kileen P., et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47 (2000) 514-519
12. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
13. Bernstein C.N., Blanchard J.F., Kliewer E., et al. Cancer risk in patients with inflammatory bowel disease. a population-based study. Cancer 91 (2001) 854-862
14. Greenstein A.J., Mullin G.E., Strauchen J.A., et al. Lymphoma in inflammatory bowel disease. Cancer 69 (1992) 1119-1123
15. Arseneau K.O., Stukenborg G.J., Connors Jr. A.F., et al. The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients. Inflamm Bowel Dis 7 (2001) 106-112
16. Palli D., Trallori G., Bagnoli S., et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 119 (2000) 647-653
17. Askling J., Brandt L., Lapidus A., et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54 (2005) 617-622
18. Lewis J.D., Bilker W.B., Brensinger C., et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121 (2001) 1080-1087
19. Colonna T., and Korelitz B.I. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 89 (1994) 362-366
20. Sandborn W.J. Rational dosing of azathioprine and 6-mercaptopurine. Gut 48 (2001) 591-592
21. DiSanti W., Rajapakse R.O., Korelitz B.I., et al. Increased incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6MP for inflammatory bowel disease. Am J Gastroenterol 99 (2004) A777
22. Dubinsky M.C., Lamothe S., Yang H.Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118 (2000) 705-713
23. Achkar J.P., Stevens T., Easley K., et al. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 10 (2004) 339-345
24. Colombel J.F., Ferrari N., Debuysere H., et al. Genotypic analysis of thiopurine S- methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118 (2000) 1025-1030
25. Lobel E.Z., Korelitz B.I., Vakher K., et al. Prolonged remission of severe Crohn's disease after fever and leukopenia caused by 6-mercaptopurine. Dig Dis Sci 49 (2004) 336-338